The Atlantic Report

Diabetic Foot Ulcers Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Diabetic Foot Ulcers Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 15
12:40 2023
Diabetic Foot Ulcers Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 30+ key pharma and biotech companies are working on 34+ pipeline drugs in the Diabetic Foot Ulcers therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Diabetic Foot Ulcers therapeutics market is anticipated to evolve immensely in the coming years owing to the increase in diabetes cases mainly due to the aging population, the rise in healthcare spending across the world, sedentary lifestyle, and the expected entry of emerging therapies containing cell therapy and gene therapy, and readily adoption of these novel therapies.

Globally, major pharma and biotech giants such as Tissue Tech Inc., Helixmith Co., Ltd., Oneness Biotech Co., Ltd., Ticeba GmbH, RHEACELL GmbH & Co. KG, and Lakewood-Amedex Inc, etc. are actively involved in developing Diabetic Foot Ulcers drugs. The emerging therapies which are under development are expected to provide efficient therapeutic approaches with a novel mechanism of action for the treatment of patients affected by Diabetic Foot Ulcers.

Diabetic Foot Ulcers Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Diabetic Foot Ulcers Market. 

The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Diabetic Foot Ulcers Pipeline Analysis

Diabetic Foot Ulcers Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Diabetic Foot Ulcers and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Diabetic Foot Ulcers market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

​​​​​Diabetic Foot Ulcerss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral

  • Parenteral

  • Intravitreal 

  • Subretinal

  • Topical

Molecule Type

Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody

  • Peptides 

  • Polymer 

  • Small molecule

  • Gene therapy

Mechanism of the Emerging Pipeline Therapies

  • Beta 1 adrenergic receptor antagonists

  • Bacterial biofilm inhibitor

  • Peptide hydrolase replacements

  • Protein replacements

  • Angiogenesis inducing agent

  • Cell replacements

  • Type 5 cyclic nucleotide phosphodiesterase inhibitor

Learn How the Ongoing Clinical & Commercial Activities will Affect the Diabetic Foot Ulcers Therapeutic Segment @

Diabetic Foot Ulcers Therapeutics Landscape

The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of diabetic foot ulcers requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.

To further improve the treatment scenario, several major pharma and biotech giants are developing therapies for Diabetic Foot ulcers. Currently, Charsire Biotechnology Corporation is leading the therapeutics market with its Diabetic Foot Ulcers drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Diabetic Foot Ulcers Therapeutics Market Include:

  • Amniox (TissueTech)

  • APstem Therapeutics

  • Aurealis Therapeutics

  • Beyond Air

  • Biotherapy Services

  • Charsire Biotechnology Corporation

  • Chiesi Farmaceutici

  • Helixmith (formerly known as ViroMed)

  • Lakewood-Amedex

  • Mallinckrodt

  • Microbion Corporation

  • NovaLead Pharma

  • Oneness Biotech

  • Rheacell (a subsidiary of Ticeba)

  • Roche

  • ShangHai HaiHe Pharmaceutical

  • TaiGen Biotechnology

  • Technophage

  • Transwell Biotech

  • ZZ Biotech

And Many Others

Diabetic Foot Ulcers Emerging and Marketed Drugs Covered in the Report Include:

  • Allo-APZ2-DFU (ABCB5 positive MSCs): Rheacell (a subsidiary of Ticeba)

  • AUP1602-C: Aurealis Therapeutics

  • Bisphosphocin Nu-3: Lakewood-Amedex

  • CSTC 1: Charsire Biotechnology Corporation

  • Engensis (VM202; Donaperminogene Seltoplasmid): Helixmith (formerly known as ViroMed)

  • ExpressGraft (C9T1 Skin Tissue): Mallinckrodt

  • MBN-101 (Pravibismane): Microbion Corporation

  • ON101 (WH-1): Oneness Biotech

  • RAPID Biodynamic Platelet Rich Plasma Haematogel: Biotherapy Services

  • TTAX01 (Neox Cord 1K): Amniox (TissueTech)

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Diabetic Foot Ulcers Current Treatment Patterns

4. Diabetic Foot Ulcers – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Diabetic Foot Ulcers Late Stage Products (Phase-III)

7. Diabetic Foot Ulcers Mid-Stage Products (Phase-II)

8. Diabetic Foot Ulcers Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Diabetic Foot Ulcers Discontinued Products

13. Diabetic Foot Ulcers Product Profiles

14. Key Companies in the Diabetic Foot Ulcers Market

15. Key Products in the Diabetic Foot Ulcers Therapeutics Segment

16. Dormant and Discontinued Products

17. Diabetic Foot Ulcers Unmet Needs

18. Diabetic Foot Ulcers Future Perspectives

19. Diabetic Foot Ulcers Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

About Author